<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of report (Date of earliest event reported): December 13, 2000
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 0-19731 94-3047598
(State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
</TABLE>
333 Lakeside Drive,
Foster City, CA 94404
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 574-3000
<PAGE>
Item 5. OTHER EVENTS
On December 13, 2000, Gilead Sciences, Inc. entered into a purchase
agreement providing for the sale, to certain initial purchasers, of $250.0
million of convertible subordinated notes ($300.0 million if the initial
purchasers' over-allotment option is exercised in full). A press release
relating to the notes is attached hereto as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
99.1 Press Release dated December 14, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
Dated: December 14, 2000 By: /s/ Mark L. Perry
--------------------------------
Mark L. Perry
Executive Vice President,
Operations
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<S> <C>
99.1 Press Release titled "Gilead Sciences Announces Private Offering of
Convertible Subordinated Notes" dated December 14, 2000.
</TABLE>
